Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL29157892 | 0.86 | ALDH1A1 (0.41) | ALDH1A1MAPTNPC1HSD17B10GFER | |
| SCHEMBL18724191 | 0.78 | MAPT (0.53) | ALDH1A1MAPTNPC1HSD17B10GFER | |
| SCHEMBL16003687 | 0.76 | ALDH1A1 (0.58) | ALDH1A1MAPTNPC1HSD17B10GFER | |
| SCHEMBL18724213 | 0.74 | ABL1 (0.53) | ALDH1A1MAPTNPC1HSD17B10GFER | |
| SCHEMBL21006642 | 0.74 | RAB9A (0.58) | ALDH1A1MAPTNPC1HSD17B10KDM4E | |
| SCHEMBL1914914 | 0.73 | LTA4H (0.47) | ALDH1A1MAPTNPC1HSD17B10GFER | |
| SCHEMBL476082 | 0.73 | LTA4H (0.56) | ALDH1A1MAPTNPC1HSD17B10GFER | |
| SCHEMBL10517092 | 0.73 | MAPT (0.46) | ALDH1A1MAPTNPC1HSD17B10GFER | |
| SCHEMBL10719025 | 0.72 | ALDH1A1 (0.61) | ALDH1A1MAPTNPC1HSD17B10GFER | |
| SCHEMBL2763422 | 0.72 | ALDH1A1 (0.63) | ALDH1A1MAPTNPC1HSD17B10GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117551093-B | Preparation method of maleic acid atorvastatin (4-chloro-2-thienyl) -2-thiazole amine) as starting material | 山东天锐医药科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117865951-A | Method for preparing 4- (4-chloro-2-thienyl) -2-thiazolamine | 苏州健雄职业技术学院 | 2024-04-12 | — | — | CN | claimed |
| CN-117551093-A | Preparation method of maleic acid atorvastatin (4-chloro-2-thienyl) -2-thiazole amine) as starting material | 山东天锐医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-119510603-A | Method for detecting related substances in atorvastatin maleate | 上海新礼泰药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-117551093-B | Preparation method of maleic acid atorvastatin (4-chloro-2-thienyl) -2-thiazole amine) as starting material | 山东天锐医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117551093-B | Preparation method of maleic acid atorvastatin (4-chloro-2-thienyl) -2-thiazole amine) as starting material | 山东天锐医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117551093-B | Preparation method of maleic acid atorvastatin (4-chloro-2-thienyl) -2-thiazole amine) as starting material | 山东天锐医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117865951-A | Method for preparing 4- (4-chloro-2-thienyl) -2-thiazolamine | 苏州健雄职业技术学院 | 2024-04-12 | — | — | CN | disclosed |
| CN-117865951-A | Method for preparing 4- (4-chloro-2-thienyl) -2-thiazolamine | 苏州健雄职业技术学院 | 2024-04-12 | — | — | CN | disclosed |
| CN-117865951-A | Method for preparing 4- (4-chloro-2-thienyl) -2-thiazolamine | 苏州健雄职业技术学院 | 2024-04-12 | — | — | CN | disclosed |
| CN-117551093-A | Preparation method of maleic acid atorvastatin (4-chloro-2-thienyl) -2-thiazole amine) as starting material | 山东天锐医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-7638536-B2 | N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally | ASTELLAS PHARMA INC. (JP) | 2009-12-29 | — | — | US | disclosed |
| US-7361658-B2 | 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[cyclobutyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-pyridyl)piperidine-4-carboxylic acid; non-peptide thrombopoietin receptor (c-mpl-Ba/F3) ligand; less immunogenicity; platelet activator based on megakaryocyte colony; thrombocytopenia; orally | ASTELLAS PHARMA INC. (JP) | 2008-04-22 | — | — | US | disclosed |
| CN-1319967-C | 2-acylaminothiazole derivative or salt thereof | YAMANOUCHI PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| CN-1835948-A | 2-acylaminothiazole derivative or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2006-09-20 | — | — | CN | disclosed |
| US-20060194844-A1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1647553-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-20050153977-A1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2005-07-14 | — | — | US | disclosed |
| CN-1639157-A | 2-acylaminothiazole derivative or salt thereof | YAMANOUCHI PHARMA CO LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-1466912-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153977-A1 | 2-Acylaminothiazole derivative or salt thereof | MPL, JAK2, ABL1 | ALDH1A1 2060/4885MAPT 4550/4885NPC1 2554/4885 |
| US-20060194844-A1 | 2-Acylaminothiazole derivative or salt thereof | MPL, JAK2, MATK | ALDH1A1 2150/4885MAPT 4790/4885NPC1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.